Charles River Laboratories International Aktie
188,26USD | 0,34USD | 0,18% |
WKN: 939391 / ISIN: US1598641074
Aktionärsstruktur
Inhaber | in % |
---|---|
Freefloat | 98,93 |
The Vanguard Group, Inc. | 11,58 |
Vanguard Group, Inc. (Subfiler) | 11,37 |
Wellington Management Co. LLP | 7,25 |
Wellington Management Co. LLP (Wellington Breakout) | 6,50 |
State Street Corp. | 4,13 |
Kayne Anderson Rudnick Investment Management LLC | 3,76 |
BlackRock Fund Advisors | 3,42 |
Allspring Global Investments LLC | 3,38 |
Vanguard Total Stock Market ETF | 3,17 |
Allspring Special Mid Cap Value Fund | 2,70 |
Vanguard 500 Index Fund | 2,62 |
Vanguard Small Cap Index Fund | 2,50 |
BlackRock Institutional Trust Co. NA | 2,39 |
Geode Capital Management LLC | 2,36 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 17 100 | 18 400 | 20 000 | 21 400 | 21 800 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,15 | 0,16 | 0,18 | 0,19 | 0,19 |
Bilanz (in Mio. USD) - Aktiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 1 021 | 1 201 | 1 274 | 1 439 | 1 609 |
Summe Anlagevermögen | 3 671 | 4 290 | 5 750 | 6 164 | 6 586 |
Summe Aktiva | 4 693 | 5 491 | 7 024 | 7 603 | 8 195 |
Bilanz (in Mio. USD) - Passiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Gesamtverschuldung/ -verbindlichkeiten | 2 025 | 2 160 | 2 953 | 3 147 | 3 127 |
Summe Fremdkapital | 3 026 | 3 347 | 4 432 | 4 579 | 4 536 |
Summe Eigenkapital | 1 666 | 2 144 | 2 592 | 3 024 | 3 659 |
Summe Passiva | 4 693 | 5 491 | 7 024 | 7 603 | 8 195 |
Adresse
251 Ballardvale Street, 01887 Wilmington | |
Telefon | +1 (781) 222-6000 |
Internet | http://www.criver.com |
Management
Barbara J. Patterson
Senior VP-Regulatory Affairs & Compliance |
Birgit Girshick
Chief Operating Officer & Executive Vice President |
Brian Bathgate
Senior Vice President-European Safety Assessment |
Colin Dunn
Senior VP, GM-Research Models & Services |
Craig B. Thompson
Independent Director |
Deborah Turner Kochevar
Independent Director |
Flavia H. Pease
Chief Financial Officer & Executive Vice President |
Foster T. Jordan
Senior Vice President-Microbial Solutions |
George E. Massaro
Lead Independent Director |
George Llado
Independent Director |
Gina M. Mullane
Chief Marketing Officer & Senior Vice President |
James C. Foster
Chairman, President & Chief Executive Officer |
John C. Ho
Chief Strategy Officer & SVP-Corporate Strategy |
Joseph W. LaPlume
Executive VP-Corporate Development & Strategy |
Julie Frearson
Chief Scientific Officer & Senior Vice President |
Kristen M. Eisenhauer
Senior VP-Client Services & Sales Management |
Mark Mintz
Chief Information Officer & Senior Vice President |
Martin W. MacKay
Director |
Matthew L. Daniel
Secretary, Chief Compliance Officer & Senior VP |
Michael Gunnar Knell
Chief Accounting Officer & Senior Vice President |
Nancy C. Andrews
Independent Director |
Reshema Kemps-Polanco
Independent Director |
Richard F. Wallman
Independent Director |
Robert J. Bertolini
Independent Director |
Shannon M. Parisotto
Senior VP-Global Operations & Controller |
Todd Spencer
Vice President-Investor Relations |
Victoria L. Creamer
Chief People Officer & Executive Vice President |
Virginia M. Wilson
Independent Director |
William D. Barbo
Chief Commercial Officer & Executive VP |